版本:
中国

BRIEF-Protalix Biotherapeutics enrolls first patient in Phase II clinical trial of OPRX-106

Nov 30 Protalix Biotherapeutics Inc

* Protalix Biotherapeutics enrolls first patient in Phase II clinical trial of OPRX-106 for the treatment of ulcerative colitis

* Protalix Biotherapeutics enrolls first patient in Phase II clinical trial of OPRX-106 for the treatment of ulcerative colitis

* Protalix Biotherapeutics Inc - "we look forward to announcing Phase II data from our AIR DNase clinical program around year-end"

* Protalix Biotherapeutics Inc - look forward to announcing data from OPRX-106 Phase II clinical trial in second half of 2017 Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐